CN112996509B - 吡啶酮a2r拮抗剂 - Google Patents
吡啶酮a2r拮抗剂 Download PDFInfo
- Publication number
- CN112996509B CN112996509B CN201980064256.XA CN201980064256A CN112996509B CN 112996509 B CN112996509 B CN 112996509B CN 201980064256 A CN201980064256 A CN 201980064256A CN 112996509 B CN112996509 B CN 112996509B
- Authority
- CN
- China
- Prior art keywords
- cancer
- alkyl
- group
- compound
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711273P | 2018-07-27 | 2018-07-27 | |
| US62/711,273 | 2018-07-27 | ||
| PCT/US2019/043608 WO2020023846A1 (en) | 2018-07-27 | 2019-07-26 | Pyridone a2r antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112996509A CN112996509A (zh) | 2021-06-18 |
| CN112996509B true CN112996509B (zh) | 2024-10-01 |
Family
ID=69182367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980064256.XA Active CN112996509B (zh) | 2018-07-27 | 2019-07-26 | 吡啶酮a2r拮抗剂 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12064433B2 (enExample) |
| EP (1) | EP3829581B1 (enExample) |
| JP (1) | JP7394831B2 (enExample) |
| KR (1) | KR102809468B1 (enExample) |
| CN (1) | CN112996509B (enExample) |
| AU (1) | AU2019312296B2 (enExample) |
| CA (1) | CA3107079A1 (enExample) |
| ES (1) | ES2982326T3 (enExample) |
| PL (1) | PL3829581T3 (enExample) |
| WO (1) | WO2020023846A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020185859A1 (en) | 2019-03-12 | 2020-09-17 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| EP3947463A4 (en) | 2019-03-29 | 2022-12-21 | Arcus Biosciences, Inc. | TREATMENT OF CANCER USING AN IDENTIFIED ADENOSINE FINGERPRINT |
| IL295569B1 (en) | 2020-03-19 | 2026-04-01 | Arcus Biosciences Inc | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2ALPHA |
| JP2021183587A (ja) * | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| AU2021292195A1 (en) | 2020-06-17 | 2023-01-05 | Arcus Biosciences, Inc. | Crystalline forms of a CD73 inhibitor and uses thereof |
| IL300976A (en) * | 2020-09-03 | 2023-04-01 | Immunesensor Therapeutics Inc | Quinoline compounds as CGAS antagonists |
| JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Ｇｐｒ８４アンタゴニストおよびその使用 |
| KR20230153387A (ko) | 2021-02-02 | 2023-11-06 | 리미널 바이오사이언시스 리미티드 | Gpr84 길항제 및 이의 용도 |
| US20240226115A1 (en) | 2021-05-21 | 2024-07-11 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
| WO2022246177A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl compounds |
| WO2023077046A1 (en) | 2021-10-29 | 2023-05-04 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| WO2023168367A1 (en) | 2022-03-02 | 2023-09-07 | Immunesensor Therapeutics, Inc. | QUINOLINE cGAS ANTAGONIST COMPOUNDS |
| WO2023215719A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| CN120091809A (zh) | 2022-10-20 | 2025-06-03 | 艾库斯生物科学有限公司 | Cd73化合物的冻干制剂 |
| WO2024097736A1 (en) | 2022-11-02 | 2024-05-10 | Arcus Biosciences, Inc. | Processes for preparing azolopyrimidine compounds |
| US20240425497A1 (en) | 2023-05-05 | 2024-12-26 | Arcus Biosciences, Inc. | Cbl-b Inhibitors and Methods of Use Thereof |
| WO2024243502A1 (en) | 2023-05-25 | 2024-11-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| US20260116868A1 (en) | 2023-10-06 | 2026-04-30 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202523302A (zh) | 2023-11-02 | 2025-06-16 | 美商阿克思生物科學有限公司 | 噻唑化合物及其使用方法 |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
| AU2025271396A1 (en) * | 2024-10-30 | 2026-05-14 | Hanmi Pharm. Co., Ltd. | Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016126570A1 (en) * | 2015-02-06 | 2016-08-11 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004092177A1 (en) | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| US7618962B2 (en) * | 2005-02-25 | 2009-11-17 | Pgx Health, Llc | Pyrazolyl substituted xanthines |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| RU2457842C2 (ru) | 2006-03-17 | 2012-08-10 | Гайлид Пало Альто, Инк. | Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина a2b |
| WO2008156580A1 (en) | 2007-06-13 | 2008-12-24 | Merck & Co., Inc. | Triazole derivatives for treating alzheimer's disease and related conditions |
| CN101801413A (zh) | 2007-07-12 | 2010-08-11 | 托勒克斯股份有限公司 | 采用gitr结合分子的联合疗法 |
| PT3023438T (pt) | 2009-09-03 | 2020-05-08 | Merck Sharp & Dohme | Anticorpos anti-gitr |
| PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| RU2627268C2 (ru) * | 2012-02-29 | 2017-08-04 | Хемоцентрикс, Инк. | Аза-арил-1Н-пиразол-1-ил-сульфонамиды |
| WO2015002994A2 (en) | 2013-07-02 | 2015-01-08 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| EP3496717A4 (en) * | 2016-08-15 | 2020-01-15 | Purdue Research Foundation | 4-substituted aminoisoquinoline derivatives |
| TWI781136B (zh) * | 2017-01-20 | 2022-10-21 | 美商阿克思生物科學有限公司 | 用於治療癌症相關病症之唑嘧啶 |
-
2019
- 2019-07-26 WO PCT/US2019/043608 patent/WO2020023846A1/en not_active Ceased
- 2019-07-26 JP JP2021504283A patent/JP7394831B2/ja active Active
- 2019-07-26 ES ES19841391T patent/ES2982326T3/es active Active
- 2019-07-26 EP EP19841391.6A patent/EP3829581B1/en active Active
- 2019-07-26 CA CA3107079A patent/CA3107079A1/en active Pending
- 2019-07-26 PL PL19841391.6T patent/PL3829581T3/pl unknown
- 2019-07-26 KR KR1020217005878A patent/KR102809468B1/ko active Active
- 2019-07-26 AU AU2019312296A patent/AU2019312296B2/en active Active
- 2019-07-26 US US17/263,016 patent/US12064433B2/en active Active
- 2019-07-26 CN CN201980064256.XA patent/CN112996509B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016126570A1 (en) * | 2015-02-06 | 2016-08-11 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
Non-Patent Citations (2)
| Title |
|---|
| Elisa Bonandi 等.The 1,2,3-triazole ring as a bioisostere in medicinal chemistry.Drug Discovery Today.2017,第22卷第1572页、第1574页图3. * |
| Idrees Mohammed 等.1,2,3-Triazoles as Amide Bioisosteres: Discovery of a New Class of Potent HIV‑1 Vif Antagonists.Journal of Medicinal Chemistry.2016,第59卷摘要、第7680页总结部分. * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019312296B2 (en) | 2025-05-29 |
| KR20210038642A (ko) | 2021-04-07 |
| EP3829581A4 (en) | 2022-04-27 |
| JP7394831B2 (ja) | 2023-12-08 |
| US12064433B2 (en) | 2024-08-20 |
| EP3829581C0 (en) | 2024-04-03 |
| CA3107079A1 (en) | 2020-01-30 |
| EP3829581A1 (en) | 2021-06-09 |
| ES2982326T3 (es) | 2024-10-15 |
| US20210161898A1 (en) | 2021-06-03 |
| AU2019312296A1 (en) | 2021-03-18 |
| PL3829581T3 (pl) | 2024-07-01 |
| KR102809468B1 (ko) | 2025-05-19 |
| WO2020023846A1 (en) | 2020-01-30 |
| EP3829581B1 (en) | 2024-04-03 |
| CN112996509A (zh) | 2021-06-18 |
| JP2021531314A (ja) | 2021-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7394831B2 (ja) | ピリドンａ２ｒアンタゴニスト | |
| ES2953349T3 (es) | Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer | |
| ES2951809T3 (es) | Derivados de quinazolina-pirazol para el tratamiento de trastornos relacionados con el cáncer | |
| TWI812494B (zh) | 用於治療癌症相關病症之唑嘧啶 | |
| WO2020018680A1 (en) | Solid forms of an azolopyrimidine compound | |
| HK40055891A (en) | Pyridone a2r antagonists | |
| HK40055891B (zh) | 吡啶酮a2r拮抗剂 | |
| HK40105495A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| HK40054296B (en) | Pyridone a2r antagonists | |
| HK40054296A (en) | Pyridone a2r antagonists | |
| HK40024629A (en) | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | |
| HK40024629B (en) | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | |
| HK40027765A (en) | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders | |
| HK40027765B (en) | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders | |
| EA038488B1 (ru) | Азолопиримидины для лечения раковых заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40055891 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |